Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A method of transfecting isolated autologous T-Lymphocytes with endogenous cytokines, for example IL-7 and IL-15, to sustain an adoptive T-lymphocyte response without systemic toxicity. More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
This invention describes improved methods for the large scale manufacture of stable disulfide-conjugated antibody therapeutics. More
Inventors at the National Institutes of Health have recently characterized and cloned both the yeast and human recombinant versions of the enzyme deoxyhypusine hydroxylase (DOHH) that catalyzes the final step in the modification of eIF5A. More
Method of diagnosing/prognosing B-cell lymphoma or leukemia development/progresssion More
These cell lines have been used to advance understanding of the molecular mechanisms of lymphomagenesis, and may be useful for the identification of molecular targets for agents that can be developed for the treatment of lymphomas and other tumors. More
Fc-IL-15 has a longer half life in vivo than naturally occurring IL-15 in a gene therapy setting and has more potent anti-tumor effects than IL-15 in some mouse tumor models. More
These compounds inhibit the deubiquitination of proteins by targeting the deubiquitination enzymes in the protein degradation pathway. More
Methods, systems and transgenic animals useful for screening, diagnosing and treating FUS1 related disorders More
New combination therapies for hematological malignancies using an immunotoxin and chemotherapeutic agent More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Hodgkin's lymphoma
- Lymphoma, AIDS-related
- Neoplastic disease
- Non-Hodgkins lymphoma
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us